Abbott Laboratories ABT

101.29 0.22 0.22% as of 25 Sep
Market cap
$174.8B
P/E
32.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Abbott Laboratories (ABT) Free cash flow margin

Abbott Laboratories's free cash flow margin over the twelve months to 30 June 2026 was 16.8%, up 0.1 percentage points from fiscal 2025 (16.7%). Over the past ten years it has ranged from 9.10% (fiscal 2015) to 20.1% (fiscal 2021); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of −7.24% and above the Healthcare sector median of 0.00%.

Free cash flow margin, annual

Annual

Period Free cash flow margin Change (points)
FY2025 16.7% 1.54
FY2024 15.1% 2.53
FY2023 12.6% (5.27)
FY2022 17.9% (2.20)
FY2021 20.1% 3.54
FY2020 16.5% 2.44
FY2019 14.1% (1.94)
FY2018 16.0% (0.15)
FY2017 16.2% 6.21
FY2016 9.98% 0.88

Against its own ten years

Low 9.10% High 20.1%
Ten-year median 16.0%
Current reading's percentile 82

Free cash flow margin against peers

Company Free cash flow margin
DXCM DexCom, Inc. compare 28.3%
EW Edwards Lifesciences Corporation compare 22.0%
SYK Stryker Corporation compare 18.2%
BSX Boston Scientific Corporation compare 17.3%
ABT Abbott Laboratories 16.8%
MDT Medtronic PLC compare 16.3%
STE STERIS plc compare 15.5%
PHG Koninklijke Philips N.V. compare 8.99%
GEHC GE HealthCare Technologies Inc. compare 7.42%
Medical Devices industry median −7.24%
Healthcare sector median 0.00%
Market median 0.00%

What Free cash flow margin is

Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.

(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue

The full definition of Free cash flow margin →

More on ABT